Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2015 - 2026)

Avalo Therapeutics (AVTX) has 12 years of Total Non-Current Liabilities data on file, last reported at $31.6 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 286.45% year-over-year to $31.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.6 million (up 286.45% YoY) and the FY2025 annual result came in at $33.4 million, up 261.97% from the prior year.
• Total Non-Current Liabilities slipped to $31.6 million in Q1 2026, from $33.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $219.1 million in Q1 2024 to a low of $8.1 million in Q4 2023.
• A 5-year average of $43.8 million and a median of $33.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities jumped 436.16% — and 2025, when it slumped 96.27%.
• Tracing AVTX's Total Non-Current Liabilities over 5 years: stood at $39.5 million in 2022, then plunged by 79.37% to $8.1 million in 2023, then rose by 13.28% to $9.2 million in 2024, then soared by 261.97% to $33.4 million in 2025, then decreased by 5.42% to $31.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $31.6 million (Q1 2026), $33.4 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.